Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
IPO Year: 1991
Exchange: NYSE
Website: haemonetics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/8/2024 | $120.00 | Outperform → Strong Buy | Raymond James |
| 9/13/2024 | $116.00 | Buy | CL King |
| 9/11/2024 | $85.00 | Neutral | BofA Securities |
| 9/10/2024 | $112.00 | Buy | BTIG Research |
| 6/12/2024 | $112.00 | Hold → Buy | Needham |
| 10/13/2022 | $90.00 | Buy | Mizuho |
| 2/9/2022 | $70.00 → $66.00 | Outperform | Raymond James |
| 1/27/2022 | Buy → Hold | Needham | |
| 1/7/2022 | $68.00 → $60.00 | Equal-Weight | Morgan Stanley |
| 12/15/2021 | $75.00 → $59.00 | Buy → Neutral | Citigroup |
10-Q - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
10-Q - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
8-K/A - HAEMONETICS CORP (0000313143) (Filer)
8-K - HAEMONETICS CORP (0000313143) (Filer)
ARS - HAEMONETICS CORP (0000313143) (Filer)
DEFA14A - HAEMONETICS CORP (0000313143) (Filer)
DEF 14A - HAEMONETICS CORP (0000313143) (Filer)
SC 13G - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the
BOSTON, March 21, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) today announced that James C. D'Arecca will join the Company as Executive Vice President, Chief Financial Officer, effective April 11, 2022. He will report directly to Chris Simon, Haemonetics' President and Chief Executive Officer. In this role, D'Arecca will oversee the Company's treasury, controllership and accounting, investor relations, tax, information technology, and financial planning and analysis functions. He succeeds William P. Burke, who last year shared his decision to retire as the Company'
Financial release accessible online BOSTON, Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI3c9f473811f94
BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
Financial release accessible online BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI5ac87cebabbb4a7aaaad3
BOSTON, July 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, August 8, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2024. The call can be accessed via teleconference at: Q1 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W
Financial release accessible online BOSTON, May 9, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 9, 2024. The conference call and webcast can be accessed with the following information: Teleconference link:https://register.vevent.com/register/BI7654787bc47144b39cb1
BOSTON, April 10, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 9, 2024. The call can be accessed via teleconference at: Q4 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.
Financial release accessible online BOSTON, Feb. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2024, which ended December 30, 2023, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 8, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BIddeef4a5eb8d4c2
BOSTON, Jan. 11, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, February 8, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 8, 2024. The call can be accessed via teleconference at: Q3 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start. A live webcast
BOSTON, Oct. 5, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2024 financial results at 6:00 am ET on Thursday, November 2, 2023. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 2, 2023. The call can be accessed via teleconference at: Q2 2024 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
Financial release accessible online BOSTON, Aug. 8, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal 2024, which ended July 1, 2023, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2023. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI161cbc44c95c40ac857474a72c5
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
4 - HAEMONETICS CORP (0000313143) (Issuer)
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update. "The Orchestra BioMed team is focused on execution of the BACKBEAT global pivotal study alongside our strategic partner, Medtronic. We are excited about the enthusiasm we have seen from the clinical community for the potential of AVIM therapy to provide these typically older, higher risk hypertension patients with a potent, programmable, always on t
Financial release accessible online BOSTON, Nov. 7, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 7, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI3c9f473811f94
BOSTON, Oct. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, November 7, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 7, 2024. The call can be accessed via teleconference at: Q2 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the ca
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
BOSTON, Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis. The VASCADE MVP XL s
Financial release accessible online BOSTON, Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2024. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BI5ac87cebabbb4a7aaaad3
CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ
BOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and the first commercial European procedures for the SavvyWire® Pre-Shaped Pressure Guidewire. The SavvyWire guidewire is the world's first and only sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI), designed to improve procedural efficiency with predictable wire performance, hemodynamic measurement and left-ventricular (LV) pacing capabilities.
BOSTON, July 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, August 8, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2024. The call can be accessed via teleconference at: Q1 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W
BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis. Haemonetics' current VASCADE portfolio includes the VASCADE system, de
Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112. The analyst says that Haemonetics has reaffirmed its “high-20%” FY26 operating margin goal. To reach this, the company must improve by approximately 600 basis points from its FY24 margin of 21.1%, writes the analyst. While the analyst earlier doubted the company’s ability to reach this target, the product mix analysis has bolstered their confidence. The analyst has identified two key factors influencing the company’s gross margin, which includes the reduction in lower-margin Plasma sales to CSL and the expansion of higher-margin Interventional Technologies sale
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Mike Matson upgraded the rating for Haemonetics Corporation (NYSE:HAE) from Hold to Buy and announced a price target of $112. Haemonetics shares fell 2.8% to close at $83.41 on Tuesday. See how other analysts view this stock. Morgan Stanley analyst Meta Marshall upgraded Ciena Corporation (NYSE:CIEN) from Equal-Weight to Overweight, while raising the price target from $53 to $55. Ciena shares rose 0.2% to settle at $45.92 on Tuesday. See how other analysts view this sto
Needham analyst Mike Matson upgrades Haemonetics (NYSE:HAE) from Hold to Buy and announces $112 price target.
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved
During the last three months, 4 analysts shared their evaluations of Haemonetics (NYSE:HAE), revealing diverse outlooks from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 2 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $110.5, a high estimate of $125.00, and
JMP Securities analyst David Turkaly maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target from $115 to $125.
Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00
CL King initiated coverage of Haemonetics with a rating of Buy and set a new price target of $116.00
BofA Securities initiated coverage of Haemonetics with a rating of Neutral and set a new price target of $85.00
BTIG Research initiated coverage of Haemonetics with a rating of Buy and set a new price target of $112.00
Needham upgraded Haemonetics from Hold to Buy and set a new price target of $112.00
Mizuho initiated coverage of Haemonetics with a rating of Buy and set a new price target of $90.00
Raymond James reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $66.00 from $70.00 previously
Needham downgraded Haemonetics from Buy to Hold
Morgan Stanley reiterated coverage of Haemonetics with a rating of Equal-Weight and set a new price target of $60.00 from $68.00 previously
Citigroup downgraded Haemonetics from Buy to Neutral and set a new price target of $59.00 from $75.00 previously